



IDT completes GMP manufacture and first stability testing points for dried cannabis flower-in-bottle and cannabis oil-in-bottle

2 April 2020, Melbourne: IDT Australia Limited (ASX: IDT) today announces that it has completed GMP manufacture and first stability testing points for dried cannabis flower-in-bottle and cannabis oil-in-bottle products.

This follows IDT's earlier announced commencement of commercial scale GMP medicinal cannabis resin solvent extraction activities utilising IDT's plant and equipment (ASX announcement: 7 January 2020). The medicinal cannabis resin produced from IDT's GMP solvent extraction process has now been formulated into oil-in-bottle finished product and reached its first stability time point.

In parallel with these activities IDT has also completed initial stability testing for the medicinal cannabis flower-in-bottle product which was GMP packaged in December 2019 (ASX announcement 19 December 2019).

"IDT is executing on its Medicinal Cannabis Manufacturing Plan to establish the Company's Boronia manufacturing campus as a commercial manufacturer of GMP medicinal cannabis Active Pharmaceutical Ingredients (API's) and Finished Dosage Forms." said IDT Australia Limited's CEO, Dr David Sparling. "The Company has now extracted medicinal cannabis resin under GMP conditions, packaged GMP medicinal cannabis flower-in-bottle and formulated and packaged GMP medicinal cannabis oil-in-bottle."

ENDS

For further information please contact:
IDT Australia Limited
Dr David Sparling – Chief Executive Officer
(03) 9801 8888

Disclosure: This ASX announcement was authorised for release by the chair, Mr Alan Fisher.